MARKET

CRIS

CRIS

Curis
NASDAQ
0.9803
-0.0068
-0.69%
Opening 11:14 01/02 EST
OPEN
0.9913
PREV CLOSE
0.9871
HIGH
1.006
LOW
0.9749
VOLUME
13.40K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
0.9600
MARKET CAP
12.67M
P/E (TTM)
-0.2667
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (1222-1226)?
Weekly Report · 12/29/2025 09:52
Weekly Report: what happened at CRIS last week (1215-1219)?
Weekly Report · 12/22/2025 09:52
CURASIGHT ANNOUNCES SUCCESSFUL DOSING OF FIRST PATIENT IN PHASE 1 TRIAL WITH UTREAT® IN BRAIN CANCER
Reuters · 12/18/2025 18:46
Weekly Report: what happened at CRIS last week (1208-1212)?
Weekly Report · 12/15/2025 09:57
After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying
NASDAQ · 12/11/2025 04:49
Curis’s Promising Clinical Developments and Strategic Trials Justify Buy Rating
TipRanks · 12/09/2025 20:05
Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study
Reuters · 12/09/2025 13:01
CURIS PROVIDES UPDATED DATA FROM ITS FRONTLINE AML TRIPLET STUDY
Reuters · 12/09/2025 13:00
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.